Overview

• Advocate Vishal Tiwari’s petition asks the Supreme Court for a court‑monitored national inquiry, transfer of all FIRs to the CBI, and immediate recall and seizure of Coldrif with NABL‑verified testing before any sale.
• Punjab and Himachal Pradesh ordered fresh bans, joining multiple states that halted sales and seized stocks, while Madhya Pradesh moved to bar two more syrups—ReLife and Respifresh TR—after detecting DEG above limits.
• Official laboratory reports declared Coldrif Batch SR‑13 ‘Not of Standard Quality,’ with DEG measured at roughly 46–49% by state drug analysts, and identified the manufacturer as Sresan Pharmaceuticals in Tamil Nadu.
• Madhya Pradesh set up an SIT, suspended drug officials, arrested paediatrician Dr. Praveen Soni, and filed an FIR against Sresan; Tamil Nadu issued a show‑cause citing over 350 critical and major lapses and stopped production at the unit.
• The Union health ministry advised against cough‑and‑cold medicines for very young children as the CDSCO launched risk‑based inspections, and Madhya Pradesh announced compensation and said it will cover treatment costs for affected children.